Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Roseman L, Nutt DJ, Carhart-Harris RL. · 2017

Read Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. by Roseman L, Nutt DJ, Carhart-Harris RL. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5776504.txt.

Description

Roseman, Nutt, and Carhart-Harris test whether the quality of a psilocybin session predicts later gains in hard to treat depression. Twenty patients took part in a trial with two dosing sessions. A standard questionnaire scored their altered state during the high dose session. Two scores stood for mystical type experience and for dread of ego loss.

The team tracked depression scores to five weeks. Experience scores predicted the five week outcome, they report. Sensory effects carried little predictive weight by contrast. The results back the view that experience quality shapes lasting benefit, a core claim of the psychedelic treatment model.

Catalog record

CREATORRoseman L, Nutt DJ, Carhart-Harris RL.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5776504

Browse the full library · About the Tower of Babel